Comparing two antiviral drugs to prevent CMV after kidney transplant
Treatments studied
Part of Blood & lymphatic, Infections clinical trials.
This study compares two medications, letermovir and valganciclovir, to see which works better at preventing CMV infection in people who have received a kidney transplant and have previously been exposed to the virus. Taking part may help reduce the risk of a serious infection after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have received a kidney transplant and have a positive test result for CMV (a common virus) before the transplant.
- You are not on dialysis and do not have severe liver problems.
- You have not had other organ transplants or a stem cell transplant.
- You are able to take medications by mouth and are not currently using illegal drugs or dependent on alcohol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
This study tests whether a blood test can help doctors decide how long to continue letermovir (a medicine that prevents a common viral infection called CMV) after a stem cell transplant. The goal is to see if a shorter course is safe and effective for some patients.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
Hear when a new CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.